<DOC>
	<DOCNO>NCT02616380</DOCNO>
	<brief_summary>The study design prospective , observational study assess effect adalimumab health-related quality life ( QoL ) work productivity patient rheumatoid arthritis ( RA ) Taiwan .</brief_summary>
	<brief_title>Real-World Outcome Adalimumab Rheumatoid Arthritis Patients Taiwan</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject diagnosis RA define 1987 revised American College Rheumatology ( ACR ) classification criterion and/or ACR/the European League Rheumatism ( EULAR ) 2010 classification criterion ( duration since diagnosis ) . Male female subject &gt; = 18 year age ( local definition accord adalimumab label ) compliance eligibility adalimumab base local label . Patients moderate severe RA define Disease Activity Score 28 Joints ( DAS28 ) Erythrocyte Sedimentation Rate ( ESR ) DAS28 C Reactive Protein ( CRP ) &gt; 3.2 Biologically treatment na√Øve initiate adalimumab baseline visit Availability clinical data previous 12 week prior baseline Ability selfcomplete patient questionnaire Subject must able willing provide write informed consent comply requirement study protocol . Patients pregnant breast feed enrolment wish become pregnant next 24 week . Participation RArelated clinical trial time enrolment , baseline point past 24 week prior baseline Patients , clinician 's view , may able accurately report QoL prior resource utilization Patients , clinician 's view , may able adhere adalimumab therapy 24 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Work productivity</keyword>
	<keyword>Quality life ( QOL )</keyword>
	<keyword>Rheumatoid arthritis ( RA )</keyword>
</DOC>